The corporate logo of Samsung Biologics Co. captured from the company’s website (Image courtesy of Yonhap)
SEOUL, Nov. 20 (Korea Bizwire) — Samsung Biologics Co. said Wednesday it has won two new contract manufacturing deals with a combined value of 930.4 billion won (US$667.7 million) from a Europe-based biopharmaceutical firm.
The deals, set to last until the end of 2031, are valued at 752.4 billion won and 178 billion won, respectively, according to the company’s regulatory filing. Other details remained undisclosed under a confidentiality agreement.
Samsung Biologics said it has secured a total of 11 deals with a combined value of 5.29 trillion won so far this year.
It marks the first time the accumulated value of the company’s deals surpassed the 5 trillion won mark annually.
Last year, the company sealed deals worth a combined 3.5 trillion won.
(Yonhap)
